Loading
A phase 3 trial of Docetaxel, Paclitaxel / nab-paclitaxel, Epirubicin, Cyclophosphamide, Fluorouracil, Lenograstim and Pegfilgrastim in Breast cancer, run by Hellenic Oncology Research Group, completed.
Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer is a phase 3 interventional study registered as NCT00431080 by Hellenic Oncology Research Group, with 478 participants recorded, started 2004-08 and reaching its primary completion in 2007-10. Interventions recorded: Docetaxel, Paclitaxel, Epirubicin, Cyclophosphamide, 5-fluoruracil, Granulocyte-colony stimulating growth factor. Conditions recorded: Breast Cancer.
Linked to the drug Lenograstim because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Hellenic Oncology Research Group, Lenograstim, Pegfilgrastim, Epirubicin and the tag pipeline.
Shares Epirubicin, Fluorouracil (5-FU), Docetaxel, Cyclophosphamide and the tag pipeline.
Shares Docetaxel, Cyclophosphamide, Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Epirubicin, Docetaxel and the tag pipeline.
Shares Pegfilgrastim, Docetaxel and the tag pipeline.
Shares Cyclophosphamide, Paclitaxel / nab-paclitaxel, Breast cancer (all types) and the tag pipeline.
Shares Pegfilgrastim, Breast cancer (all types) and the tag pipeline.